MTOR and central nervous system cancer: In addition, endogenous mTOR co-immunoprecipitated with RIOK2 and BYSL in BYSL-overexpressing cells (Figure 6C) and endogenous BYSL co-immunoprecipitated with RIOK2 and mTOR in U251 glioma cells (Figure 6D).